Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.65
Bid: 18.40
Ask: 19.65
Change: 0.00 (0.00%)
Spread: 1.25 (6.793%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 19.65
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

11 Apr 2012 07:00

RNS Number : 0556B
BATM Advanced Communications Ld
11 April 2012
 



 

 

 

11 April 2012

 

BATM Advanced Communications Limited

Interim Management Statement

BATM Advanced Communications Limited ("BATM" or the "Company") (LSE: BVC), a leading designer and producer of telecom systems and medical laboratory diagnostic and sterilisation systems, is today issuing its Interim Management Statement for the period from 1 January 2012 to 31 March 2012.

Current trading update 

Total revenues in the first quarter of 2012 (Q1) were $24.9 million, slightly ahead of our plan, and compared with $27.4 million on a like for like basis for the equivalent period in 2011, which excludes revenues from the discontinued legacy telecom business.

 

During the first quarter of the year the sales mix was 52% from the Telecoms division and 48% from the Medical division compared to 66% and 34% respectively in the first quarter of 2011. Gross margin was lower during the first quarter of 2012 than over the same period of 2011 as a result of a higher mix of Medical sales but nonetheless met the company's internal targets. Significant improvement in gross margin was achieved in the Medical division over the same period last year despite the fact that we are still in the early stages of production in our diagnostic division.

 

Financial position 

The Company's balance sheet remains strong and at March 31 the effective cash balance stood at $42.7 million, a decrease of $4.2 million compared to the position at December 31 2011, mainly as a result of repayment of a long term loan that is expected to generate a one off gain of approximately $0.7 million.

 

Telecom Division

Our Telecom division is, following its re-organisation, making progress in line with our previous guidance. New customers are being won worldwide as the division focuses on being a key supplier to next generation telecoms networks.

 

Medical Division

The Medical division continues to make significant progress in gaining validation for its products and in growing its market presence. This progress can be evidenced by our recent announcement that the Company had received CE certification for its Detect HIV 4th Generation Total Screening Kit, which proved 100% accurate in independent testing.

 

The improved margins that we reported have been demonstrated in all three areas of operations: diagnostics, sterilisation and distribution. This is in line with our long term target to increase our operating margins in the Medical division to the levels of our Telecom division.

 

 

Outlook BATM has achieved its goals for the first quarter and significant progress has been made in the Medical Division.

 

Despite the challenging commercial macro environment we believe we are on track to achieve our strategic, operating and financial targets for the full year and remain cautiously optimistic regarding the outlook for both of our divisions in the medium term.

 

 

- Ends -

 

Enquiries

 

BATM Advanced Communications +972 9866 2525   

Dr Zvi Marom, Chief Executive

Ofer Bar-Ner, CFO

 

Threadneedle Communications 020 7653 9850

Josh Royston / Graham Herring

 

FinnCap 020 7220 0500

Marc Young

 

Shore Capital 020 7408 4090 

Pascal Keane

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBUGDSCGBBGDG
Date   Source Headline
2nd May 20247:00 amRNSBATM selected for TB diagnostics programme
18th Apr 20247:00 amRNSBATM to deliver Edgility to new Tier 1 customer
8th Apr 20247:00 amRNSBATM awarded new Edgility contract from Cemex
3rd Apr 20247:00 amRNSAnnual Financial Report
26th Mar 20247:00 amRNSBATM receives $2.3m cyber security orders
12th Mar 20247:00 amRNSFull Year Results
29th Feb 20247:00 amRNSNotice of Results
2nd Jan 20247:00 amRNSTotal Voting Rights
30th Nov 20237:03 amRNSBlock Listing Application
27th Nov 20237:00 amRNSBlock Listing Interim Review
30th Oct 20237:00 amRNSBATM receives $3m cyber security order
23rd Oct 20237:00 amRNSADOR Diagnostics secures $7.5m investment
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSNew Edgility order for US Emergency Services
9th Oct 20237:00 amRNSResponse to recent developments in Israel
6th Sep 20237:00 amRNSBATM receives $3.4m cyber security contract
29th Aug 20237:00 amRNSInterim Results
13th Jul 202311:30 amRNSResult of AGM and Director Appointment
8th Jun 20237:00 amRNSNotice of Annual General Meeting
6th Jun 20237:00 amRNSCapital Markets Day
5th Jun 20237:00 amRNSNew contract win for Edgility
10th May 20232:30 pmRNSCapital Markets Day and Investor Presentation
17th Apr 20237:00 amRNSEdgility rollout progressing ahead of schedule
4th Apr 20233:30 pmRNSAnnual Financial Report
6th Mar 20237:00 amRNSFull Year Results
24th Feb 20237:00 amRNSNotice of Results
1st Feb 20237:00 amRNSAppointment of Chief Financial Officer
9th Jan 20237:00 amRNSBATM receives $26m cyber security order
3rd Jan 20233:30 pmRNSGrant of Options
21st Dec 202212:00 pmRNSResult of AGM
21st Dec 20227:00 amRNSTransaction in Own Shares and TVR
20th Dec 20227:00 amRNSTransaction in Own Shares and TVR
19th Dec 20227:00 amRNSTransaction in Own Shares and TVR
16th Dec 20227:00 amRNSTransaction in Own Shares and TVR
15th Dec 20227:00 amRNSTransaction in Own Shares and TVR
14th Dec 20227:00 amRNSTransaction in Own Shares and TVR
13th Dec 20227:00 amRNSTransaction in Own Shares and TVR
9th Dec 20227:00 amRNSTransaction in Own Shares and TVR
8th Dec 20227:00 amRNSTrading Update
25th Nov 20221:00 pmRNSBlock Listing Interim Review
24th Nov 20224:00 pmRNSNotice of Annual General Meeting
27th Oct 20227:00 amRNSADOR and BIOASTER to develop STI diagnostic tests
18th Oct 20227:00 amRNSMulti-year contract with CityFibre for Edgility
6th Oct 20227:00 amRNSDirectorate Changes
24th Aug 20227:00 amRNSInterim Results
19th Jul 20227:00 amRNSAppointment of CEO of ADOR Diagnostics
11th Jul 20227:00 amRNSBATM partners with CityFibre for Edgility
16th Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20227:00 amRNSBlock Listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.